BioSpace News Archive

Takeda Pharmaceutical Company Limited announced that it has entered into agreements to divest its Xiidra® 5% product to Novartis and its TachoSil® Fibrin Sealant Patch to Ethicon as part of its strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.

Fuse Medical, Inc., announced that it has filed its quarterly report on Form 10-Q for the first quarter ended March 31, 2019, with the United States Securities and Exchange Commission, on Tuesday, May 7, 2019.

Cortexyme, Inc. announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions.

Titan Pharmaceuticals, Inc. will announce its first quarter 2019 financial results after market close on Wednesday, May 15, 2019.

Milestone Pharmaceuticals Inc. announced the pricing of its upsized initial public offering of 5,500,000 of its common shares at a public offering price of $15.00 per share.

Sapio Sciences is pleased to announce the availability of Exemplar ELN Essentials, a self-service SaaS solution.

GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX

Conference Call with Live Audio Webcast on Tuesday May 14th at 9:00 AM ET

McKesson Corporation reported that revenues for the fourth quarter ended March 31, 2019, were $52.4 billion compared to $51.6 billion a year ago, an increase of 2% on a reported basis and an increase of 3% on an FX-adjusted basis.

MYOS RENS Technology Inc. announced its financial results for the first quarter ended March 31, 2019.